Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective
Open Access
- 1 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 44 (1), 95-105
- https://doi.org/10.1007/s40264-020-01035-x
Abstract
Introduction Evidence-based clinical data on coronavirus disease 2019 (COVID-19) pharmacotherapies are scarce. Objective This study documented and characterized COVID-19 cases reported in individuals receiving treatment with Pfizer pharmaceutical products and cases that reported use of Pfizer pharmaceutical products for COVID-19 treatment. Methods This retrospective observational review leveraged the Pfizer safety database containing adverse event data collected in association with use of Pfizer products between 1 October, 2019, and 25 June, 2020; the database includes worldwide adverse event data from various sources. Selected Medical Dictionary for Drug Regulatory Activities (MedDRA(R)) Preferred Terms and subsequent clinical review were used to characterize COVID-19 cases. Results Over 1500 relevant cases were identified over an 8-month period. In cases that reported COVID-19, immunosuppressant/immunomodulating agents, followed by anticoagulant/antithrombic agents and corticosteroids, were the most frequently reported agents. The frequent reporting of immunosuppressant/immunomodulating agents among cases of COVID-19 suggests increased vulnerability to infection among treated patients, either because of immunosuppressive effects of certain agents or the nature of the underlying treated condition. In cases involving off-label pharmacotherapy use for the treatment of COVID-19-related conditions, the most frequently reported therapeutic classes included antibiotics, antimalarial agents, antivirals/antiretroviral agents, immunosuppressant/immunomodulating agents, corticosteroids, anticoagulants, and immunoglobulin/interferons. The most frequently reported pharmacotherapeutic agents were azithromycin and chloroquine/hydroxychloroquine, followed by lopinavir-ritonavir, ceftriaxone, and tofacitinib. The most frequently reported clinical adverse events associated with azithromycin (as sole therapy or combined with chloroquine/hydroxychloroquine) include electrocardiogram QT prolonged, drug interaction, hepatitis, diarrhea, and hepatitis acute. Regarding cardiac-related events, 19% (120/645) of azithromycin cases reported events associated with QT prolongation/torsade de pointes (which included seven fatal cardiac events). The most frequently reported clinical adverse events associated with other commonly used agents are also presented. Conclusions This pharmacovigilance surveillance study provides a unique characterization of cases in which a broad range of pharmaceutical products was reported in relation to COVID-19.Funding Information
- Pfizer
This publication has 16 references indexed in Scilit:
- Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New YorkThe New England Journal of Medicine, 2020
- Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysisTravel Medicine and Infectious Disease, 2020
- Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on TofacitinibInflammatory Bowel Diseases, 2020
- Potential Effects of Coronaviruses on the Cardiovascular System A ReviewJAMA Cardiology, 2020
- COVID-19 in a high-risk dual heart and kidney transplant recipientAmerican Journal of Transplantation, 2020
- COVID-19 in rheumatic disease patients on immunosuppressive agentsSeminars in Arthritis and Rheumatism, 2020
- Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case reportAmerican Journal of Transplantation, 2020
- Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experienceJournal of Thrombosis and Haemostasis, 2020
- Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune ResponseCurrent Cardiology Reports, 2020